Hosted by Cancer Research UK and the University of Leeds
Advancements in cancer treatments and technologies hold potential to revolutionize patient care and outcomes, but the process of translating innovative research into clinical practice and policy decisions is a complex one.
This panel discussion explores how we can tackle the challenges around timely translation of new treatments and technologies for cancer into policy and care. The session will look at how high-level evidence informs international guideline, regulatory and policy decisions that ultimately determine patient treatment and care.
The session will be chaired by David Sebag-Montefiore, Professor of Clinical Oncology and Health Research.
Guest speaker and panellist: Owen Jackson - Director of Policy, Cancer Research UK
Owen Jackson is Director of Policy at Cancer Research UK. He joined the charity in 2022 from the UK’s Government Office for Science, where he was Deputy Director for Global Issues and Opportunities, responsible for developing science and research policy with the Government Chief Scientific Adviser, Sir Patrick Vallance. Owen has a wealth of experience in strategy, policy development and programme delivery from over a decade of experience across the Civil Service. Owen is a Leeds alumni, previously completing his PhD in microbiology at the University of Leeds.
Panellists
- David Meads - Associate Professor of Health Economics. Member of the NICE Technology Appraisal Panel D.
- Katie Spencer - University Academic Fellow and Consultant in Clinical Oncology. NHS Digital’s National Clinical Lead for Radiotherapy Data, which is used to inform radiotherapy policy.
- David Cairns - Professor of Clinical Trials Research, and expert on practice-changing clinical trial design and delivery.